Why India's biotech giants are looking to Australia

India's biotech sector is growing at a staggering rate, expanding from about AUD 14.3 billion to more than AUD 236 billion in little over a decade. But at BioAsia 2026, India's innovators weren't just talking about their home advantage - they were keen to know more about Australia’s fast-tracked clinical trials, data governance and R&D strengths.

For Indian companies racing to get first-in-human or proof-of-concept data, Australia’s efficient, risk-based regulatory system offers rigorous safety standards and real competitive advantage. Our Clinical Trial Notification (CTN) pathways allow trials to start immediately after ethics approval, meaning most studies get green-lit within 6 to 12 weeks. Given traditional regulatory timelines can take up to 16 weeks, Indian innovators are paying attention.

Inauguration of the Team Australia pavilion at BioAsia 2026

Opening doors with data

The US Food and Drug Administration (FDA) and European Medicines Agency (EMA) accept Phase 1 data from Australian clinical trials, meaning Australian trial results carry weight in Boston, Paris and other global hubs. For Indian firms targeting advanced biotech markets, Australia offers a validated, fast track pathway for early phase development.

To Australia’s Phase I and II expertise, rapid approvals, globally credible data, significant R&D tax benefits, India brings late-phase scale, massive patient populations, cost-effective manufacturing and development volume.

This means Australian biotech firms can leverage India’s manufacturing scale and patient access, and Indian companies can use Australia’s regulatory speed and data credibility to access US and EU-regulated markets. Together, this creates a practical pathway from molecule to market.

What Australian businesses need to know

For Australian firms in clinical trials, biotech or life sciences, India’s opportunity isn't just about competing on cost or manufacturing scale. It's also about positioning Australia as the early-phase partner of choice for innovators who need fast, credible and globally recognised data.

For Indian companies innovating, scaling and actively looking for partners to help them compete globally, Australia has much to offer.

If you are interested in Australia-India biotech opportunities, contact india@austrade.gov.au.